XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue
 3 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Disaggregation of Revenue
The following table presents revenue by category:
Three Months Ended June 30,
20242023
Amount
% of Revenue
Amount
% of Revenue
(in thousands, except percentages)
Point in Time (1)
PGS$24,397 60 %$31,759 52 %
Telehealth5,039 13 %8,285 14 %
Consumer services29,436 73 %40,044 66 %
Research services344 1 %2,353 3 %
Total$29,780 74 %$42,397 69 %
Over Time (1)
PGS$8,109 20 %$5,270 9 %
Telehealth1,608 4 %2,238 4 %
Consumer services9,717 24 %7,508 13 %
Research services917 2 %10,959 18 %
Total$10,634 26 %$18,467 31 %
 
Revenue by Category (1)
PGS$32,506 80 %$37,029 61 %
Telehealth6,647 17 %10,523 18 %
Consumer services39,153 97 %47,552 79 %
Research services1,261 3 %13,312 21 %
Total$40,414 100 %$60,864 100 %
(1)There was no Therapeutics revenue for the three months ended June 30, 2024 and 2023.
The following table summarizes revenue by region based on the shipping address of customers:
Three Months Ended June 30,
20242023
Amount
% of Revenue
Amount
% of Revenue
(in thousands, except percentages)
United States$35,285 87 %$43,326 71 %
United Kingdom2,124 5 %14,355 24 %
Canada2,015 5 %2,170 3 %
Other regions990 3 %1,013 2 %
Total$40,414 100 %$60,864 100 %
Breakage Revenue
The Company sells through multiple channels, including direct-to-consumer via the Company’s website and through online retailers. If the customer does not return the kit for processing, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognized breakage revenue from unreturned kits of $4.0 million and $4.6 million for the three months ended June 30, 2024 and 2023, respectively.
Contract Balances
Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts associated with contractual rights related to consideration for performance obligations and are included in prepaid expenses and other current assets on the condensed consolidated balance sheets. The amount of contract assets was immaterial as of June 30, 2024 and March 31, 2024.
Contract liabilities consist of deferred revenue. As of June 30, 2024 and March 31, 2024, deferred revenue for consumer services was $51.3 million and $52.3 million, respectively. Of the $52.3 million of deferred revenue for consumer services as of March 31, 2024, the Company recognized $21.6 million as revenue during the three months ended June 30, 2024.
As of June 30, 2024 and March 31, 2024, deferred revenue for research services was $21.7 million and $22.5 million, respectively. As of June 30, 2024 and March 31, 2024, deferred revenue for research services included $20.8 million and $21.0 million, respectively, of related party deferred revenue. Of the $22.5 million of deferred revenue for research services as of March 31, 2024, the Company recognized $1.0 million as revenue during the three months ended June 30, 2024, which included related party revenue of $0.2 million for the three months ended June 30, 2024.
Remaining Performance Obligations
The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be billed and recognized as revenue in future periods. The Company has utilized the practical expedient available under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”) to not disclose the value of unsatisfied performance obligations for PGS and telehealth as those contracts have an expected length of one year or less. As of June 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations for research services was $26.4 million. The Company expects to recognize revenue of approximately 69% of this amount over the next 12 months and the remainder thereafter. During the three months ended June 30, 2024 and 2023, revenue recognized for performance obligations satisfied in prior periods were immaterial.